Amantadine Hydrochloride

ApprovedSmall molecule

Novartis

Amantadine Hydrochloride is one of 115 small molecule programs targeting Cerebral Palsy. It is currently in Approved.

Indications

Total Trials

Active Trials

114

Competitors

Pipeline

Status by Indication[3][1]

Indication

Cerebral PalsyActive, not recruiting

Brain InjuryActive, not recruiting

Multiple SclerosisActive, not recruiting

COVID-19Active, not recruiting

Cerebral PalsyApproved

Active, not recruiting

Brain InjuryApproved

Active, not recruiting

Multiple SclerosisPhase 3

Active, not recruiting

COVID-19Phase 3

Active, not recruiting

Competition

Competitive Landscape

1931 competitors in COVID-19

#DrugCompanyPhaseTrials

Amantadine Hydrochloride

Novartis

Approved

1 2

Bnt162b2

BioNTech

Preclinical

29 3

Nadroparin

GSK

Preclinical

1 4

HB-Admscs

HHope Biosciences Research Foundation

Preclinical

4 5

Aprotinin

Bayer

Preclinical

1 6

Antithrombin-III

Octapharma

Preclinical

1 7

Interferon-Gamma

SSPP Pharmaclon Ltd.

Preclinical

1 8

MRNA COVID-19 Vaccine

Novartis

Preclinical

4 9

Exoflo

DDirect Biologics, LLC

Preclinical

3 10

Tpa

UUniversity of Florida

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2030

Phase 2/3Recruiting

Trial

NCT04302870

Clinical

Trials by Indication[1]

Brain Injury4 trials

Effectiveness of Amantadine Hydrochloride for Treatment of Severe Traumatic Brain Injury (TBI)

Completed·JJFK Medical Center·Phase 2/3·NCT00970944·184 enrolled

Study to Assess the Safety of Amantadine Hydrochloride (HCl) Intravenous (IV) Solution (MR-301) in Patients With Severe Traumatic Brain Injury (TBI).

Active, not recruiting·SSHINKEI Therapeutics, Inc·Phase 2·NCT06253923·45 enrolled

Amantadine for the Treatment of Traumatic Brain Injury Irritability and Aggression: A Multi-site Study

Completed·WWake Forest University Health Sciences·N/A·NCT00779324·168 enrolled

Show 1 more trial

Effect of Amantadine Administration on Spatial Functioning Following Traumatic Brain Injury

Unknown status·—·Phase 4·NCT02321761·10 enrolled

Amantadine2 trials

Amantadine for Treatment of Symptoms of the Post-traumatic Confusional State

Completed·MMethodist Rehabilitation Center·Phase 4·NCT00693121·79 enrolled

Safety and Pharmacokinetic Effects of Oseltamivir Alone or in Combination With Amantadine

Completed· Novartis logo

Novartis·Phase 1·NCT00416962·18 enrolled

COVID-191 trial

The Use of Amantadine in the Prevention of Progression and Treatment of COVID-19 Symptoms

Unknown status·—·Phase 3·NCT04854759·200 enrolled

Trial1 trial

Motor Neurone Disease - Systematic Multi-Arm Adaptive Randomised Trial

Recruiting·UUniversity of Edinburgh·Phase 2/3·NCT04302870·1,150 enrolled

Multiple Sclerosis1 trial

Amantadine and Transcranial Magnetic Stimulation for Treating Fatigue in Multiple Sclerosis

Unknown status·HHospital San Carlos, Madrid·Phase 3·NCT05809414·144 enrolled

1 more indication

Cerebral Palsy1 trial

Amantadine in Treating Cognitive & Motor Impairments in Adolescents and Adults With Cerebral Palsy

Terminated·—·Phase 4·NCT04273737·11 enrolled

Sources

References

[1]
ClinicalTrials.gov — 10 trial records for Amantadine Hydrochloride. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Amantadine Hydrochloride compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Amantadine Hydrochloride. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Novartis company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: Novartis

Amantadine Hydrochloride

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2030

Trials by Indication[1]

Brain Injury4 trials

Amantadine2 trials

COVID-191 trial

Trial1 trial

Multiple Sclerosis1 trial

Cerebral Palsy1 trial

References

Drug Info

Quick Facts

Related News